Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.

Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N.

Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7.

PMID:
31699709
2.

Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.

Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J, Thin TH, Lehrer D, Donovan M, Posner M, Misiukiewicz K, Greenbaum B, Salazar A, Friedlander P, Bhardwaj N.

Clin Cancer Res. 2018 Oct 15;24(20):4937-4948. doi: 10.1158/1078-0432.CCR-17-1866. Epub 2018 Jun 27.

3.

Laparoscopic Assessment to Determine the Likelihood of Achieving Optimal Cytoreduction in Patients Undergoing Primary Debulking Surgery for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Andikyan V, Kim A, Gretz HF 3rd, Zakashansky K, Prasad-Hayes M, Beddoe AM, Dottino P, Mandeli J, Chuang L.

Am J Clin Oncol. 2018 Oct;41(10):938-942. doi: 10.1097/COC.0000000000000413.

PMID:
29624506
4.

Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53.

Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D.

Clin Cancer Res. 2017 Sep 15;23(18):5446-5459. doi: 10.1158/1078-0432.CCR-17-0342. Epub 2017 Jun 19.

5.

Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years.

McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A.

J Oncol. 2016;2016:4324863. doi: 10.1155/2016/4324863. Epub 2016 Jun 13.

6.

Decision-Making in Breast Cancer Surgery: Where Do Patients Go for Information?

Schmidt H, Cohen A, Mandeli J, Weltz C, Port ER.

Am Surg. 2016 May;82(5):397-402.

PMID:
27215718
7.

Lactation opposes pappalysin-1-driven pregnancy-associated breast cancer.

Takabatake Y, Oxvig C, Nagi C, Adelson K, Jaffer S, Schmidt H, Keely PJ, Eliceiri KW, Mandeli J, Germain D.

EMBO Mol Med. 2016 Apr 1;8(4):388-406. doi: 10.15252/emmm.201606273.

8.

Early Childhood Adversity and its Associations With Anxiety, Depression, and Distress in Women With Breast Cancer.

McFarland DC, Andreotti C, Harris K, Mandeli J, Tiersten A, Holland J.

Psychosomatics. 2016 Mar-Apr;57(2):174-84. doi: 10.1016/j.psym.2015.11.008. Epub 2015 Nov 30.

9.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with liver involvement.

Berger Y, Aycart S, Tabrizian P, Agmon Y, Mandeli J, Heskel M, Hiotis S, Sarpel U, Labow DM.

J Surg Oncol. 2016 Mar;113(4):432-7. doi: 10.1002/jso.24153. Epub 2016 Jan 25.

PMID:
26804119
10.

ReCAP: Would Women With Breast Cancer Prefer to Receive an Antidepressant for Anxiety or Depression From Their Oncologist?

McFarland DC, Johnson Shen M, Harris K, Mandeli J, Tiersten A, Holland J, McFarland DC, Johnson Shen M, Harris K, Mandeli J, Tiersten A, Holland J.

J Oncol Pract. 2016 Feb;12(2):172-4; e197-206. doi: 10.1200/JOP.2015.006833. Epub 2016 Jan 19.

11.

Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size.

Wang Q, Luan W, Warren L, Fiel MI, Blank S, Kadri H, Mandeli J, Hiotis SP.

J Immunother. 2016 Jan;39(1):36-44. doi: 10.1097/CJI.0000000000000104.

PMID:
26641260
12.

Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.

Berger Y, Aycart S, Mandeli JP, Heskel M, Sarpel U, Labow DM.

Surg Oncol. 2015 Sep;24(3):264-9. doi: 10.1016/j.suronc.2015.06.013. Epub 2015 Jun 23.

PMID:
26143715
13.

Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.

Chen HM, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M, Sung M, Ferris R, Kao J, Wang LH, Pan PY, Ko EC, Chen SH.

Clin Cancer Res. 2015 Sep 15;21(18):4073-4085. doi: 10.1158/1078-0432.CCR-14-2742. Epub 2015 Apr 28.

14.

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N.

Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29.

15.

Downstaging cancer in rural Africa.

Ngoma T, Mandeli J, Holland JF.

Int J Cancer. 2015 Jun 15;136(12):2875-9. doi: 10.1002/ijc.29348. Epub 2014 Dec 3.

16.

Digital breast tomosynthesis changes management in patients seen at a tertiary care breast center.

Margolies L, Cohen A, Sonnenblick E, Mandeli J, Schmidt PH, Szabo J, Patel N, Hermann G, Weltz C, Port E.

ISRN Radiol. 2014 Mar 3;2014:658929. doi: 10.1155/2014/658929. eCollection 2014.

17.

Comparative outcomes of elderly stage I lung cancer patients treated with segmentectomy via video-assisted thoracoscopic surgery versus open resection.

Smith CB, Kale M, Mhango G, Neugut AI, Hershman DL, Mandeli JP, Wisnivesky JP.

J Thorac Oncol. 2014 Mar;9(3):383-9. doi: 10.1097/JTO.0000000000000083.

18.

Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.

Blank S, Wang Q, Fiel MI, Luan W, Kim KW, Kadri H, Mandeli J, Hiotis SP.

Ann Surg Oncol. 2014 Mar;21(3):986-94.

PMID:
24232510
19.

Survival analysis of robotic versus traditional laparoscopic surgical staging for endometrial cancer.

Cardenas-Goicoechea J, Shepherd A, Momeni M, Mandeli J, Chuang L, Gretz H, Fishman D, Rahaman J, Randall T.

Am J Obstet Gynecol. 2014 Feb;210(2):160.e1-160.e11. doi: 10.1016/j.ajog.2013.10.871. Epub 2013 Oct 28.

PMID:
24176895
20.

Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease.

Sigel K, Mhango G, Cohen J, Halm EA, Mandeli J, Strauss G, Wisnivesky J.

Ann Surg Oncol. 2013 Mar;20(3):1013-9. doi: 10.1245/s10434-012-2717-4. Epub 2012 Nov 1.

PMID:
23115004
21.

KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation.

Liu X, Gomez-Pinillos A, Loder C, Carrillo-de Santa Pau E, Qiao R, Unger PD, Kurek R, Oddoux C, Melamed J, Gallagher RE, Mandeli J, Ferrari AC.

Am J Pathol. 2012 Sep;181(3):1007-16. doi: 10.1016/j.ajpath.2012.06.008. Epub 2012 Jul 20.

22.

Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice.

Lu M, Merali S, Gordon R, Jiang J, Li Y, Mandeli J, Duan X, Fallon J, Holland JF.

Genes Cancer. 2011 Oct;2(10):985-92. doi: 10.1177/1947601911436199.

23.

Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2011 Dec;55(6):1325-31. doi: 10.1016/j.jhep.2011.02.034. Epub 2011 Apr 13.

24.

PAR, a protein involved in the cell cycle, is functionally related to chromosomal passenger proteins.

Platica M, Ionescu A, Ivan E, Holland JF, Mandeli J, Platica O.

Int J Oncol. 2011 Mar;38(3):777-85. doi: 10.3892/ijo.2011.900. Epub 2011 Jan 11.

PMID:
21225229
25.

Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer.

Wisnivesky JP, Arciniega J, Mhango G, Mandeli J, Halm EA.

Thorax. 2011 Apr;66(4):287-93. doi: 10.1136/thx.2010.148601. Epub 2010 Dec 2.

26.

Retraction: A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.

Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL.

J Natl Cancer Inst. 2010 Feb 24;102(4):283. doi: 10.1093/jnci/djq027. No abstract available.

27.

Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.

Osman K, Elliott B, Mandeli J, Scigliano E, Malone A, Isola L, Grosskreutz C.

Am J Hematol. 2010 Apr;85(4):249-54. doi: 10.1002/ajh.21633.

28.

Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.

Sinitsyn Y, Malone A, Mandeli J, Grosskreutz C, Osman K, Scigliano E, Shi P, Isola L.

Cytotherapy. 2009;11(4):457-63. doi: 10.1080/14653240902849770.

PMID:
19499401
29.

The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene.

Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL.

Hum Gene Ther. 2009 Jul;20(7):751-8. doi: 10.1089/hum.2008.145. Retraction in: Hum Gene Ther. 2010 Mar;21(3):363.

30.

Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.

Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, Fallon J, Mandeli J, Woo SL.

Cancer Gene Ther. 2009 Mar;16(3):266-78. doi: 10.1038/cgt.2008.74. Epub 2008 Oct 10.

31.

A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.

Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL.

J Natl Cancer Inst. 2008 Oct 1;100(19):1389-400. doi: 10.1093/jnci/djn308. Epub 2008 Sep 23. Retraction in: Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL. J Natl Cancer Inst. 2010 Feb 24;102(4):283.

32.

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD.

J Clin Oncol. 2008 Jun 20;26(18):2992-8. doi: 10.1200/JCO.2007.15.9947.

33.

rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.

Wu L, Huang TG, Meseck M, Altomonte J, Ebert O, Shinozaki K, García-Sastre A, Fallon J, Mandeli J, Woo SL.

Hum Gene Ther. 2008 Jun;19(6):635-47. doi: 10.1089/hum.2007.163.

34.

Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation.

Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, Woo SL.

Mol Ther. 2007 Dec;15(12):2194-202. Epub 2007 Oct 30.

35.

Expression of Wnt5A and Wnt10B in non-immortalized breast cancer cells.

Fernandez-Cobo M, Zammarchi F, Mandeli J, Holland JF, Pogo BG.

Oncol Rep. 2007 Apr;17(4):903-7.

PMID:
17342334
36.

Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.

Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, Mandeli J, O'Connell MJ, Waxman S, Germain D.

J Natl Cancer Inst. 2006 Sep 6;98(17):1238-47.

PMID:
16954476
37.

Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment.

Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H, Livak KJ, Gallagher RE, Mandeli J.

J Clin Oncol. 2006 Jul 1;24(19):3081-8.

PMID:
16809733
38.

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.

Hochster HS, Plimack ER, Mandeli J, Wadler S, Runowicz C, Goldberg G, Speyer J, Wallach R, Muggia F; New York Gynecologic Oncology Group (and phase II consortium) and the Eastern Cooperative Oncology.

Gynecol Oncol. 2006 Feb;100(2):324-9. Epub 2005 Oct 25.

PMID:
16253316
39.

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.

Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M.

Oncologist. 2005 Oct;10(9):718-27.

40.

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.

Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ.

Gynecol Oncol. 2004 Apr;93(1):144-8.

PMID:
15047228
41.

A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells.

Platica M, Ivan E, Holland JF, Ionescu A, Chen S, Mandeli J, Unger PD, Platica O.

Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1560-5. Epub 2004 Jan 26.

42.

Transformation of NIH 3T3 cells by enhanced PAR expression.

Platica M, Ivan E, Ionescu A, Holland JF, Mora G, Tindall DJ, Mandeli J, Unger PD, Platica O.

Biochem Biophys Res Commun. 2004 Feb 13;314(3):891-6.

PMID:
14741720
43.

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM.

J Clin Oncol. 2004 Jan 1;22(1):120-6.

PMID:
14701774
44.

High prevalence of MMTV-like env gene sequences in gestational breast cancer.

Wang Y, Melana SM, Baker B, Bleiweiss I, Fernandez-Cobo M, Mandeli JF, Holland JF, Pogo BG.

Med Oncol. 2003;20(3):233-6.

PMID:
14514972
45.

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.

Schwartz JD, Schwartz M, Mandeli J, Sung M.

Lancet Oncol. 2002 Oct;3(10):593-603. Review.

PMID:
12372721
46.
47.

Assessment of inspiratory flow limitation in children with sleep-disordered breathing by a nasal cannula pressure transducer system.

Serebrisky D, Cordero R, Mandeli J, Kattan M, Lamm C.

Pediatr Pulmonol. 2002 May;33(5):380-7.

PMID:
11948984
48.

Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver.

Sung MW, Chen SH, Thung SN, Zhang DY, Huang TG, Mandeli JP, Woo SL.

Hum Gene Ther. 2002 Apr 10;13(6):731-43.

PMID:
11936972
49.

13-cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients: report of a phase II randomized study.

Ferrari AC, Stone N, Stock R, Bednar M, Esseesse I, Singh H, Baldwin Y, Mandeli J.

J Clin Oncol. 2002 Jan 15;20(2):538-44.

PMID:
11786584
50.

Stable lower PAR expression decreased DU145 prostate cancer cell growth in SCID mice.

Platica M, Ivan E, Chen S, Holland JF, Gil J, Mandeli J, Platica O.

Prostate. 2001 Nov 1;49(3):200-7.

PMID:
11746265

Supplemental Content

Loading ...
Support Center